229 related articles for article (PubMed ID: 14657088)
1. Pharmacokinetic interaction between voriconazole and ciclosporin A following allogeneic bone marrow transplantation.
Groll AH; Kolve H; Ehlert K; Paulussen M; Vormoor J
J Antimicrob Chemother; 2004 Jan; 53(1):113-4. PubMed ID: 14657088
[TBL] [Abstract][Full Text] [Related]
2. Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients.
Romero AJ; Le Pogamp P; Nilsson LG; Wood N
Clin Pharmacol Ther; 2002 Apr; 71(4):226-34. PubMed ID: 11956505
[TBL] [Abstract][Full Text] [Related]
3. Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation.
Marty FM; Lowry CM; Cutler CS; Campbell BJ; Fiumara K; Baden LR; Antin JH
Biol Blood Marrow Transplant; 2006 May; 12(5):552-9. PubMed ID: 16635790
[TBL] [Abstract][Full Text] [Related]
4. Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patients.
Berge M; Guillemain R; Boussaud V; Pham MH; Chevalier P; Batisse A; Amrein C; Dannaoui E; Loriot MA; Lillo-Le Louet A; Billaud EM
Transpl Infect Dis; 2009 Jun; 11(3):211-9. PubMed ID: 19302272
[TBL] [Abstract][Full Text] [Related]
5. Voriconazole serum concentrations in prophylactically treated acute myelogenous leukaemia patients.
Rüping MJ; Müller C; Vehreschild JJ; Böhme A; Mousset S; Harnischmacher U; Frommolt P; Wassmer G; Drzisga I; Hallek M; Cornely OA
Mycoses; 2011 May; 54(3):230-3. PubMed ID: 19889174
[TBL] [Abstract][Full Text] [Related]
6. The effect of enteral nutrition supplements on serum voriconazole levels.
Williams D
J Oncol Pharm Pract; 2012 Mar; 18(1):128-31. PubMed ID: 21733905
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic interaction between everolimus and antifungal triazoles in a liver transplant patient.
Pea F; Baccarani U; Tavio M; Cojutti P; Adani GL; Londero A; Baraldo M; Franceschi L; Furlanut M; Viale P
Ann Pharmacother; 2008 Nov; 42(11):1711-6. PubMed ID: 18812562
[TBL] [Abstract][Full Text] [Related]
8. Monitoring plasma voriconazole levels following intravenous administration in critically ill patients: an observational study.
Myrianthefs P; Markantonis SL; Evaggelopoulou P; Despotelis S; Evodia E; Panidis D; Baltopoulos G
Int J Antimicrob Agents; 2010 May; 35(5):468-72. PubMed ID: 20188523
[TBL] [Abstract][Full Text] [Related]
9. Voriconazole-induced blistering in the setting of graft versus host disease: A report of 2 patients.
Conlon JD; Dauenhauer M; Tonkovic-Capin V; Talano J; Margolis D; Drolet BA; Fairley JA
J Am Acad Dermatol; 2008 Mar; 58(3):484-7. PubMed ID: 18280346
[TBL] [Abstract][Full Text] [Related]
10. Clinical application of voriconazole concentrations in the treatment of invasive aspergillosis.
Howard A; Hoffman J; Sheth A
Ann Pharmacother; 2008 Dec; 42(12):1859-64. PubMed ID: 19017830
[TBL] [Abstract][Full Text] [Related]
11. Dosing voriconazole in an obese patient.
Dickmeyer NJ; Kiel PJ
Clin Infect Dis; 2011 Oct; 53(7):745. PubMed ID: 21846833
[No Abstract] [Full Text] [Related]
12. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole.
Trifilio S; Singhal S; Williams S; Frankfurt O; Gordon L; Evens A; Winter J; Tallman M; Pi J; Mehta J
Bone Marrow Transplant; 2007 Sep; 40(5):451-6. PubMed ID: 17589527
[TBL] [Abstract][Full Text] [Related]
13. Oral voriconazole dose in children: one size does not fit all.
Goutelle S; Larcher R; Padoin C; Mialou V; Bleyzac N
Clin Infect Dis; 2010 Oct; 51(7):870; author reply 871. PubMed ID: 20809842
[No Abstract] [Full Text] [Related]
14. [Update on voriconazole].
Dtsch Med Wochenschr; 2003 Aug; 128(33):1738. PubMed ID: 12968630
[No Abstract] [Full Text] [Related]
15. A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML).
Vehreschild JJ; Böhme A; Buchheidt D; Arenz D; Harnischmacher U; Heussel CP; Ullmann AJ; Mousset S; Hummel M; Frommolt P; Wassmer G; Drzisga I; Cornely OA
J Infect; 2007 Nov; 55(5):445-9. PubMed ID: 17822770
[TBL] [Abstract][Full Text] [Related]
16. Steady-state pharmacokinetics of micafungin and voriconazole after separate and concomitant dosing in healthy adults.
Keirns J; Sawamoto T; Holum M; Buell D; Wisemandle W; Alak A
Antimicrob Agents Chemother; 2007 Feb; 51(2):787-90. PubMed ID: 17116670
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and safety of 14 days intravenous voriconazole in allogeneic haematopoietic stem cell transplant recipients.
Brüggemann RJ; Blijlevens NM; Burger DM; Franke B; Troke PF; Donnelly JP
J Antimicrob Chemother; 2010 Jan; 65(1):107-13. PubMed ID: 19933691
[TBL] [Abstract][Full Text] [Related]
18. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes.
Pascual A; Calandra T; Bolay S; Buclin T; Bille J; Marchetti O
Clin Infect Dis; 2008 Jan; 46(2):201-11. PubMed ID: 18171251
[TBL] [Abstract][Full Text] [Related]
19. Clinical pharmacokinetics of voriconazole.
Levêque D; Nivoix Y; Jehl F; Herbrecht R
Int J Antimicrob Agents; 2006 Apr; 27(4):274-84. PubMed ID: 16563707
[TBL] [Abstract][Full Text] [Related]
20. Rethinking the use of voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients.
Brown J; Freeman BB
Bone Marrow Transplant; 2005 Jul; 36(2):177. PubMed ID: 15908975
[No Abstract] [Full Text] [Related]
[Next] [New Search]
